Skip to Main Content
TABLE 2

Integrated β-cell secretory responses (insulin, C-peptide, and ISR) to oral glucose (50 g in 400 ml H2O) and adjustable (isoglycemic) intravenous glucose infusion (20% wt/vol), and calculated incretin effects (percent of the β-cell secretory response after oral glucose) in patients with chronic pancreatitis and secondary diabetes, patients with chronic pancreatitis and NGT, patients with type 2 diabetes, and healthy subjects

Patients with chronic pancreatitis and secondary diabetes*Patients with chronic pancreatitis and NGTPatients with type 2 diabetesHealthy subjects§
n (F/M) 2/6 2/6 2/6 2/6 
Integrated β-cell secretory responses     
    Insulin (nmol/l per 4 h)     
        Oral 8.8 ± 1.7§ 10.9 ± 1.8 12.1 ± 2.3 18.4 ± 3.1 
        Intravenous 5.5 ± 1.3 3.0 ± 0.7 6.8 ± 1.8 5.2 ± 1.7 
        Oral-intravenous 3.4 ± 1.0§¶ 7.8 ± 1.5*¶ 5.3 ± 1.6§¶ 13.1 ± 3.0*¶ 
    C-peptide (nmol/l per 4 h     
        Oral 127 ± 20 186 ± 37 154 ± 28 186 ± 21 
        Intravenous 87 ± 13 62 ± 14 96 ± 14 88 ± 11 
        Oral-intravenous 40 ± 11*§ 124 ± 29*¶ 58 ± 18¶ 98 ± 20*¶ 
    ISR (nmol/l per kg)     
        Oral 687 ± 110 698 ± 169 783 ± 127 649 ± 61 
        Intravenous 455 ± 61 222 ± 53* 511 ± 114 305 ± 39 
        Oral-intravenous 166 ± 63*§ 476 ± 135* 272 ± 68¶ 345 ± 55*¶ 
Relative incretin effects (%)     
    Insulin 36 ± 7 68 ± 7* 44 ± 9 73 ± 6* 
    C-peptide 26 ± 7 67 ± 6* 31 ± 9 52 ± 7* 
    ISR 31 ± 5 68 ± 6* 34 ± 7 53 ± 5* 
Average 31 ± 4 68 ± 3* 36 ± 6 60 ± 4* 
Patients with chronic pancreatitis and secondary diabetes*Patients with chronic pancreatitis and NGTPatients with type 2 diabetesHealthy subjects§
n (F/M) 2/6 2/6 2/6 2/6 
Integrated β-cell secretory responses     
    Insulin (nmol/l per 4 h)     
        Oral 8.8 ± 1.7§ 10.9 ± 1.8 12.1 ± 2.3 18.4 ± 3.1 
        Intravenous 5.5 ± 1.3 3.0 ± 0.7 6.8 ± 1.8 5.2 ± 1.7 
        Oral-intravenous 3.4 ± 1.0§¶ 7.8 ± 1.5*¶ 5.3 ± 1.6§¶ 13.1 ± 3.0*¶ 
    C-peptide (nmol/l per 4 h     
        Oral 127 ± 20 186 ± 37 154 ± 28 186 ± 21 
        Intravenous 87 ± 13 62 ± 14 96 ± 14 88 ± 11 
        Oral-intravenous 40 ± 11*§ 124 ± 29*¶ 58 ± 18¶ 98 ± 20*¶ 
    ISR (nmol/l per kg)     
        Oral 687 ± 110 698 ± 169 783 ± 127 649 ± 61 
        Intravenous 455 ± 61 222 ± 53* 511 ± 114 305 ± 39 
        Oral-intravenous 166 ± 63*§ 476 ± 135* 272 ± 68¶ 345 ± 55*¶ 
Relative incretin effects (%)     
    Insulin 36 ± 7 68 ± 7* 44 ± 9 73 ± 6* 
    C-peptide 26 ± 7 67 ± 6* 31 ± 9 52 ± 7* 
    ISR 31 ± 5 68 ± 6* 34 ± 7 53 ± 5* 
Average 31 ± 4 68 ± 3* 36 ± 6 60 ± 4* 

Data are means ± SE. Significant differences (P < 0.05) between responses to oral glucose and isoglycemic intravenous glucose infusion within each group (¶) and significant differences (P < 0.05) in integrated β-cell secretory responses and incretin effects, respectively, between the four groups are indicated.

*

Compared with patients with chronic pancreatitis and secondary diabetes.

Compared with patients with chronic pancreatitis and NGT.

Compared with patients with type 2 diabetes.

§

Compared with healthy subjects.

Close Modal

or Create an Account

Close Modal
Close Modal